Risk factors and clinical characteristics for Stenotrophomonas maltophilia infection in an acute care hospital in Japan: a single-center retrospective study.

Michiya Tanuma, Takayuki Sakurai, Hidemasa Nakaminami, Masayo Tanaka
Author Information
  1. Michiya Tanuma: Department of Pharmacy, NTT Medical Center Tokyo, 5-9-22 Higashi-Gotanda, Shinagawa-Ku, Tokyo, 141-8625, Japan. michiya.tanuma@east.ntt.co.jp. ORCID
  2. Takayuki Sakurai: Department of Infectious Diseases, NTT Medical Center Tokyo, 5-9-22 Higashi-Gotanda, Shinagawa-Ku, Tokyo, 141-8625, Japan.
  3. Hidemasa Nakaminami: Department of Clinical Microbiology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan.
  4. Masayo Tanaka: Department of Pharmacy, NTT Medical Center Tokyo, 5-9-22 Higashi-Gotanda, Shinagawa-Ku, Tokyo, 141-8625, Japan.

Abstract

BACKGROUND: Stenotrophomonas maltophilia (S. maltophilia) is a Gram-negative pathogen that causes opportunistic infections. Although the mortality rate among patients with nosocomial infections caused by S. maltophilia is high, the risk factors for infection vary among studies. Moreover, S. maltophilia is highly resistant to several classes of antimicrobial agents. To date, few studies on S. maltophilia have been conducted in Japan, and the details remain unclear. Therefore, the objective of this study was to investigate the risk factors associated with S. maltophilia infection and the antimicrobial susceptibility of S. maltophilia isolates identified in our hospital.
METHODS: In this study, we investigated the risk factors associated with S. maltophilia infection and clinical characteristics isolated from patients at the NTT Medical Center Tokyo (Tokyo, Japan). We retrospectively examined the S. maltophilia isolates and the corresponding patients between March 2022 and August 2023.
RESULTS: Fifty-eight patients with S. maltophilia isolated (median age, 80.5 years; age range, 49-100 years; 70.7% male) were enrolled in this study. Twelve cases (20.7%) were placed in the S. maltophilia infection group and 46 cases were placed in the S. maltophilia colonization group. Central venous (CV) catheterization and higher Sequential Organ Failure Assessment (SOFA) scores were identified as risk factors for S. maltophilia infection. In addition, the 30-day mortality rate was significantly higher, and the survival rate was significantly lower in patients with S. maltophilia infection. The antimicrobial susceptibility rates of S. maltophilia were as follows: 28.6% for ceftazidime, 2.4% for cefozopran, 96.6% for levofloxacin, 100% for minocycline, and 98.3% for trimethoprim-sulfamethoxazole.
CONCLUSIONS: In actual clinical practice, S. maltophilia was more frequently isolated from sputum. However, most of the cases were colonization, and cases of infection were rare. Early treatment initiation should be considered for S. maltophilia infection in cases where the pathogen is detected from sterile sites, such as blood cultures and pleural fluid or from sputum in cases with a high SOFA score and CV catheter insertion.

Keywords

References

  1. Malawi Med J. 2021 Jun;33(2):82-84 [PMID: 34777703]
  2. J Antimicrob Chemother. 2016 Dec;71(12):3620 [PMID: 27516472]
  3. Support Care Cancer. 2018 Jun;26(6):1953-1960 [PMID: 29307014]
  4. Eur J Clin Microbiol Infect Dis. 2007 Apr;26(4):229-37 [PMID: 17334747]
  5. PLoS One. 2016 Mar 21;11(3):e0152132 [PMID: 26999818]
  6. Antimicrob Agents Chemother. 2008 Oct;52(10):3823-5 [PMID: 18644963]
  7. Ann Pharmacother. 2024 Jul;58(7):698-704 [PMID: 37776160]
  8. Infect Drug Resist. 2020 May 28;13:1559-1566 [PMID: 32547125]
  9. Clin Infect Dis. 2024 Aug 07;: [PMID: 39108079]
  10. Microb Drug Resist. 2010 Jun;16(2):111-7 [PMID: 20438350]
  11. J Mol Microbiol Biotechnol. 2001 Apr;3(2):255-64 [PMID: 11321581]
  12. Front Med (Lausanne). 2022 Jan 12;8:808391 [PMID: 35096895]
  13. N Engl J Med. 1997 Jan 23;336(4):243-50 [PMID: 8995086]
  14. J Infect Dev Ctries. 2014 Aug 13;8(8):1000-5 [PMID: 25116665]
  15. Crit Care. 2006;10(5):R143 [PMID: 17026755]
  16. Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1419-28 [PMID: 22057419]
  17. PLoS One. 2016 Jun 16;11(6):e0157693 [PMID: 27310255]
  18. Eur J Clin Microbiol Infect Dis. 2010 May;29(5):605-8 [PMID: 20177726]
  19. Afr Health Sci. 2020 Sep;20(3):1118-1123 [PMID: 33402956]
  20. Heart Lung. 1999 Mar-Apr;28(2):134-41 [PMID: 10076113]
  21. Future Microbiol. 2009 Aug;4(6):655-60 [PMID: 19659422]
  22. Thorax. 2003 May;58(5):377-82 [PMID: 12728155]
  23. Front Microbiol. 2015 Sep 02;6:893 [PMID: 26388847]
  24. Expert Rev Anti Infect Ther. 2019 Nov;17(11):877-893 [PMID: 31658838]
  25. BMC Microbiol. 2008 Sep 16;8:148 [PMID: 18793450]
  26. Int J Infect Dis. 2012 Aug;16(8):e603-7 [PMID: 22698885]
  27. Antimicrob Agents Chemother. 2010 Jun;54(6):2735-7 [PMID: 20368399]
  28. Int J Infect Dis. 2017 May;58:18-21 [PMID: 28257816]
  29. Virulence. 2013 Apr 1;4(3):223-9 [PMID: 23380871]
  30. Emerg Infect Dis. 2007 Apr;13(4):559-65 [PMID: 17553270]
  31. New Microbes New Infect. 2015 May 14;7:8-14 [PMID: 26110061]
  32. Intern Med. 2006;45(7):419-28 [PMID: 16679695]
  33. Medicine (Baltimore). 2016 Aug;95(31):e4375 [PMID: 27495046]
  34. Front Med (Lausanne). 2023 May 05;10:1163439 [PMID: 37215718]
  35. Antimicrob Resist Infect Control. 2021 Jan 22;10(1):19 [PMID: 33482916]
  36. Future Microbiol. 2009 Nov;4(9):1103-9 [PMID: 19895214]
  37. J Antimicrob Chemother. 2010 Mar;65(3):483-9 [PMID: 20071366]
  38. Respirology. 2008 Nov;13(6):880-5 [PMID: 18657061]
  39. J Hosp Infect. 2004 May;57(1):1-7 [PMID: 15142709]
  40. J Med Microbiol. 2017 Aug;66(8):1102-1109 [PMID: 28771141]
  41. J Antimicrob Chemother. 2008 Nov;62(5):889-94 [PMID: 18662945]
  42. Lancet Infect Dis. 2009 May;9(5):312-23 [PMID: 19393961]
  43. Clin Infect Dis. 1996 Mar;22(3):508-12 [PMID: 8852971]
  44. Microb Drug Resist. 2023 Apr;29(4):115-126 [PMID: 36897754]
  45. J Microbiol Immunol Infect. 2012 Apr;45(2):120-6 [PMID: 22154599]
  46. J Microbiol Immunol Infect. 2022 Feb;55(1):107-113 [PMID: 33500210]
  47. Antimicrob Agents Chemother. 2002 Aug;46(8):2582-7 [PMID: 12121936]
  48. Sci Rep. 2023 Feb 28;13(1):3392 [PMID: 36854720]

Word Cloud

Created with Highcharts 10.0.0maltophiliaSinfectionfactorscasespatientsriskstudyStenotrophomonasrateantimicrobialsusceptibilityclinicalisolatedpathogeninfectionsmortalityamonghighstudiesJapanassociatedisolatesidentifiedhospitalcharacteristicsTokyoage7%placedgroupcolonizationCVhigherSOFAsignificantly6%sputumRiskAntimicrobialBACKGROUND:Gram-negativecausesopportunisticAlthoughnosocomialcausedvaryMoreoverhighlyresistantseveralclassesagentsdateconducteddetailsremainunclearThereforeobjectiveinvestigateMETHODS:investigatedNTTMedicalCenterretrospectivelyexaminedcorrespondingMarch2022August2023RESULTS:Fifty-eightmedian805 yearsrange49-100 years70maleenrolledTwelve2046CentralvenouscatheterizationSequentialOrganFailureAssessmentscoresaddition30-daysurvivallowerratesfollows:28ceftazidime24%cefozopran96levofloxacin100%minocycline983%trimethoprim-sulfamethoxazoleCONCLUSIONS:actualpracticefrequentlyHoweverrareEarlytreatmentinitiationconsidereddetectedsterilesitesbloodculturespleuralfluidscorecatheterinsertionacutecareJapan:single-centerretrospectiveresistancePneumonia

Similar Articles

Cited By